🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

HepatologyICD-10: B18.2

Find Recruiting Clinical Trials for Hepatitis C

Search HCV treatment, cirrhosis, liver fibrosis, and reinfection prevention trials — matched to your genotype and treatment history.

🔍 Search Hepatitis C Trials →

About Hepatitis C

Hepatitis C virus (HCV) infection affects approximately 58 million people globally and 2.4 million Americans. Chronic HCV infection leads to liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Direct-acting antiviral (DAA) therapies — particularly pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) — achieve cure (sustained virologic response, SVR) in >95% of patients with 8–12 week oral therapy. Despite excellent treatment, HCV clinical trials remain highly active in: treatment of remaining difficult-to-cure populations, managing cirrhosis and fibrosis regression post-SVR, preventing HCC, and addressing reinfection in high-risk populations.

What Types of Hepatitis C Clinical Trials Exist?

HCV trials target populations with remaining unmet needs: people who inject drugs (PWID) with access barriers, patients with HCV and advanced cirrhosis, post-SVR liver disease progression (fibrosis regression, HCC surveillance and prevention), HCV-related extrahepatic manifestations (cryoglobulinemia, glomerulonephritis), HCV reinfection prevention in high-risk groups, and next-generation DAA combinations for rare or multi-drug-resistant genotypes. HCV genotype (1–6), treatment history (DAA-naive vs. experienced), fibrosis stage (F0–F4 by FibroScan or biopsy), and cirrhosis status determine trial eligibility.

Find Recruiting Hepatitis C Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Hepatitis C Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for hepatitis C?▾
Recruiting HCV trials include post-SVR liver disease management (fibrosis regression monitoring, HCC prevention), DAA access and adherence programs for hard-to-reach populations, reinfection prevention in PWID, next-generation antiviral combinations, HCV-related extrahepatic disease (cryoglobulinemia vasculitis), and liver transplant HCV-positive donor recipient trials.
I was already cured of HCV — are there still trials for me?▾
Yes. Post-SVR (cured) patients with advanced liver disease (cirrhosis, portal hypertension) are a major trial population. Trials study fibrosis regression rates, HCC surveillance optimization, portal hypertension management, and whether additional antifibrotic therapy improves outcomes after SVR in cirrhotic patients. Post-SVR HCC risk persists in patients with cirrhosis and is an active research area.
What is my HCV genotype and why does it matter?▾
HCV has 6 major genotypes (1–6). While pangenotypic DAA regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) treat all genotypes equally, genotype still affects some trial eligibility criteria and historical treatment response data. Genotype 3 with cirrhosis has historically had the lowest cure rates and may have dedicated trial programs. Know your genotype from your initial HCV workup.

Related Conditions

HIV / AIDSChronic Kidney DiseaseColorectal Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.